Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization

By Alvarez C.   Cremades N.   Blasco N.   Bernabeu R.  

Human Reproduction, Vol. 12, Iss. 11, 1997-11 ,pp. : 2366-2369

Oxford University Press

Access to resources Recommend Favorite

Case report. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization

By de Jong D  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 573-575

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization

By Beckers N.G.M.  

Human Reproduction, Vol. 15, Iss. 1, 2000-01 ,pp. : 43-49

Oxford University Press

Access to resources Recommend Favorite

Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins

By Oliveira J.B.A.   Baruffi R.L.R.   Mauri A.L.   Petersen C.G.   Borges M.C.   Franco J.G.  

Human Reproduction, Vol. 12, Iss. 11, 1997-11 ,pp. : 2515-2518

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles

By Albano C.  

Human Reproduction, Vol. 14, Iss. 6, 1999-06 ,pp. : 1426-1430

Oxford University Press

Access to resources Recommend Favorite